Market Cap | 82.91K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.67M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | 12M | PEG | - | EPS past 5Y | 144.95% | 200D Avg Chg | -5.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | 5.00% | 52W High Chg | -50.00% |
Recommedations | - | Quick Ratio | 0.31 | Shares Outstanding | 21.82M | 52W Low Chg | 900.00% |
Insider Own | - | ROA | -7.62% | Shares Float | - | Beta | -76.60 |
Inst Own | - | ROE | - | Shares Shorted/Prior | 41.23K/40.94K | Price | 0.00010 |
Gross Margin | 47.13% | Profit Margin | -38.90% | Avg. Volume | 126 | Target Price | - |
Oper. Margin | -5.56% | Earnings Date | - | Volume | 1,500 | Change | 0.00% |
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
Dougherty & Co. | Buy | Jul 17, 12 |